X0206 3 2016-04-06 0 0001636282 Aeglea BioTherapeutics, Inc. AGLE 0001655962 York Charles N II C/O AEGLEA BIOTHERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, SUITE 250 AUSTIN TX 78746 0 1 0 0 Chief Financial Officer and VP Common Stock 7504 D Series A Preferred Stock 0 Common Stock 9523 I By IRA Series B Preferred Stock 0 Common Stock 2037 I By IRA Series B Preferred Stock 0 Common Stock 1324 D Employee Stock Option (right to buy) 3.465 2025-03-31 Common Stock 10183 D Employee Stock Option (right to buy) 3.465 2025-03-31 Common Stock 22258 D Employee Stock Option (right to buy) 3.465 2025-03-31 Common Stock 15027 D Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. The stock option vested and became exercisable as to 25% of the shares subject to the option on July 16, 2015, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option vested and became exercisable as to 25% of the shares subject to the option on March 20, 2016, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on March 20, 2017, and thereafter vests as to 1/16th of the shares at the end of each three month period in equal installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. /s/ Charles N. York II 2016-04-06